Page 121 - 中国全科医学2022-11

·1398· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

for locally advanced or metastatic nonsquamous NSCLC：a to receive pembrolizumab or placebo：a secondary analysis of a
randomized，double-blind，phase 3 study （oncology pRogram by randomized clinical trial［J］. JAMA Oncol，2020，6（4）：
InnovENT anti-PD-1-11）［J］. J Thorac Oncol，2020，15（10）： 519-527. DOI：10.1001/jamaoncol.2019.5570.
1636-1646. DOI：10.1016/j.jtho.2020.07.014. ［54］Squibb B-M. A Single-Arm，Open-Label，Multicenter
［41］LAM V K，FORDE P M. Another brick in the wall：sintilimab plus Clinical Trial With Nivolumab （BMS-936558） for Subjects
chemotherapy in advanced lung cancer［J］. J Thorac Oncol， With Histologically Confirmed Stage Ⅲ（Unresectable） or
2020，15（10）：1556-1558. DOI：10.1016/j.jtho.2020.08.013. Stage Ⅳ Melanoma Progressing Post Prior Treatment Containing an
［42］LEE A，KEAM S J. Tislelizumab：first approval［J］. Drugs， Anti-CTLA4 Monoclonal Antibody （CheckMate 172）. https://
2020，80（6）：617-624. DOI：10.1007/s40265-020-01286-z. ClinicalTrials.gov/show/NCT02156804，2014.
［43］SONG Y Q，WU J Q，CHEN X C，et al. A single-arm， ［55］MIGDEN M R，KHUSHALANI N I，CHANG A L S，et al.
multicenter，phase II study of camrelizumab in relapsed or refractory Cemiplimab in locally advanced cutaneous squamous cell
classical Hodgkin lymphoma［J］. Clin Cancer Res，2019，25（24）： carcinoma：results from an open-label，phase 2，single-arm
7363-7369. DOI：10.1158/1078-0432.CCR-19-1680. trial［J］. Lancet Oncol，2020，21（2）：294-305. DOI：
［44］QIN S，REN Z，MENG Z，et al. Camrelizumab in patients 10.1016/s1470-2045（19）30728-4.
with previously treated advanced hepatocellular carcinoma：a ［56］SHI Y K，SU H，SONG Y P，et al. Safety and activity of sintilimab
multicentre，open-label，parallel-group，randomised，phase in patients with relapsed or refractory classical Hodgkin lymphoma
2 trial［J］. Lancet Oncol，2020，21（4）：571-580. DOI： （ORIENT-1）：a multicentre，single-arm，phase 2 trial［J］.
10.1016/s1470-2045（20）30011-5. Lancet Haematol，2019，6（1）：e12-e19. DOI：10.1016/
［45］HUANG J，XU J M，CHEN Y，et al. Camrelizumab versus S2352-3026（18）30192-3.
investigator&apos；s choice of chemotherapy as second-line therapy ［57］LAN C Y，SHEN J X，WANG Y，et al. Camrelizumab plus
for advanced or metastatic oesophageal squamous cell carcinoma apatinib in patients with advanced cervical cancer （CLAP）：
（ESCORT）：a multicentre，randomised，open-label，phase a multicenter，open-label，single-arm，phase II trial［J］.
3 study［J］. Lancet Oncol，2020，21（6）：832-842. DOI： J Clin Oncol，2020，38（34）：4095-4106. DOI：
10.1016/S1470-2045（20）30110-8. 10.1200/JCO.20.01920.
［46］FAN Y，ZHAO J，WANG Q M，et al. Camrelizumab plus apatinib ［58］Roche H-L. A Study of Atezolizumab in Participants With Locally
in extensive-stage SCLC （PASSION）：a multicenter，two- Advanced or Metastatic Urothelial Bladder Cancer（Cohort 2，
stage，phase 2 trial［J］. J Thorac Oncol，2021，16（2）：299- https://ClinicalTrials.gov/show/NCT02108652，2014.
309. DOI：10.1016/j.jtho.2020.10.002. ［59］Astrazeneca. A Global Study to Assess the Effects of MEDI4736
［47］HERBST R S，SORIA J C，KOWANETZ M，et al. Predictive Following Concurrent Chemoradiation in Patients With
correlates of response to the anti-PD-L1 antibody MPDL3280A in Stage Ⅲ Unresectable Non-Small Cell Lung Cancer. https://
cancer patients［J］. Nature，2014，515（7528）：563-567. ClinicalTrials.gov/show/NCT02125461，2014.
DOI：10.1038/nature14011. ［60］KASTNER D L，AKSENTIJEVICH I，GOLDBACH-
［48］APOLO A B，INFANTE J R，BALMANOUKIAN A，et al. MANSKY R. Autoinflammatory disease reloaded：a clinical
Avelumab，an anti-programmed death-ligand 1 antibody，in perspective［J］. Cell，2010，140（6）：784-790. DOI：
patients with refractory metastatic urothelial carcinoma：results from 10.1016/j.cell.2010.03.002. MCGONAGLE D，MCDERMOTT M
a multicenter，phase ib study［J］. J Clin Oncol，2017，35（19）： F. A proposed classification of the immunological diseases［J］.
2117-2124. DOI：10.1200/JCO.2016.71.6795. PLoS Med，2006，3（8）：e297. DOI：10.1371/journal.
［49］GAISER M R，BONGIORNO M，BROWNELL I. PD-L1 pmed.0030297.
inhibition with avelumab for metastatic Merkel cell carcinoma［J］. ［61］BRAHMER J R，LACCHETTI C，THOMPSON J A. Management
Expert Rev Clin Pharmacol，2018，11（4）：345-359. DOI： of immune-related adverse events in patients treated with immune
10.1080/17512433.2018.1445966. checkpoint inhibitor therapy：American society of clinical oncology
［50］GULLAPALLI S，REMON J，HENDRIKS L E L，et al. Update clinical practice guideline summary［J］. J Oncol Pract，2018，14
on targeted therapies for advanced non-small cell lung cancer： （4）：247-249. DOI：10.1200/JOP.18.00005.
durvalumab in context［J］. Onco Targets Ther，2020，13： ［62］MALLETT G，LAURENCE A，AMARNATH S. Programmed cell
6885-6896. DOI：10.2147/OTT.S259308. death-1 receptor （PD-1）-mediated regulation of innate lymphoid
［51］STEWART R，MORROW M，HAMMOND S A，et al. cells［J］. Int J Mol Sci，2019，20（11）：2836. DOI：
Identification and characterization of MEDI4736，an antagonistic 10.3390/ijms20112836.
anti-PD-L1 monoclonal antibody［J］. Cancer Immunol Res， ［63］MARIOTTI F R，QUATRINI L，MUNARI E，et al. Innate
2015，3（9）：1052-1062. DOI：10.1158/2326-6066.CIR-14- lymphoid cells：expression of PD-1 and other checkpoints in normal
0191. and pathological conditions［J］. Front Immunol，2019，10：910.
［52］GUZIK K，ZAK K M，GRUDNIK P，et al. Small-molecule DOI：10.3389/fimmu.2019.00910.
inhibitors of the programmed cell death-1/programmed death-ligand ［64］TUMINO N，MARTINI S，MUNARI E，et al. Presence of innate
1 （PD-1/PD-L1） interaction via transiently induced protein states lymphoid cells in pleural effusions of primary and metastatic
and dimerization of PD-L1［J］. J Med Chem，2017，60（13）： tumors：Functional analysis and expression of PD-1 receptor［J］.
5857-5867. DOI：10.1021/acs.jmedchem.7b00293. Int J Cancer，2019，145（6）：1660-1668. DOI：
［53］EGGERMONT A M M，KICINSKI M，BLANK C U，et al. 10.1002/ijc.32262.
Association between immune-related adverse events and recurrence-
free survival among patients with stage Ⅲ melanoma randomized （下转第1405页）